Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Amylase concentration linked to mortality in guinea pigs
Researchers say the digestive enzyme is often overlooked.
Guinea pigs with high plasma concentrations of amylase face increased mortality.

Researchers have revealed the clinical significance of plasma amylase to the lifespan of guinea pigs.

The new study has found that guinea pigs which recorded particularly high plasma concentrations of amylase were more likely to die within 30 days of biochemistry analysis.

To investigate the causes of mortality in guinea pigs, researchers retrospectively analysed the medical records of 278 guinea pigs treated in four different institutions. The guinea pigs had all undergone a biochemistry panel, had their plasma concentrations measured and had a follow-up 30 days later.

The guinea pigs had been brought to the institutions for a number of reasons, including emergencies, sickness and wellness appointments. Among their diagnoses were integument disease, reproductive issues and gastrointestinal disease.

Using this data, the research team analysed the guinea pigs’ survival rates and drew comparisons to their amylase concentrations.

The analysis revealed that guinea pigs which recorded an elevated level of plasma amylase concentration (1910 to 3985 U/L) were seven times more likely to die in the next 30 days than those with a concentration within the reference intervals (1339 to 1573 U/L).

It also found increased mortality risk among guinea pigs with high blood urea nitrogen (BUN) concentrations. Guinea pigs with BUN concentrations higher 62 mg/dL had a 30 times increase in their mortality risk.

Ashley Souza and Sarah Ozawa, lead authors of the study, said: “Guinea pigs can be a challenging species to treat, especially when they enter a veterinary hospital in critical condition.

“It is our hope that this study provides further diagnostic tools for veterinarians to use when explaining options and prognosis to an owner, helping guide treatment and care for this species.”

Amylase is a digestive enzyme, which researchers say is often overlooked. Its clinical significance is largely misunderstood, however researchers now say that high amylase levels could indicate a sick guinea pig requires more diagnostic testing or supportive care.

The researchers say that, because the prognostic capacity of amylase is limited, the amylase concentration data should only be used as part of the bigger clinical picture and should not solely inform veterinary decisions.

The full study can be found in the Journal of Small Animal Practice.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.